Website profile

Pharmadispatch

News of the Day Anticipated therapies and not-so-anticipated dominate July PBAC agenda GSK brings Melbourne discovered treatment 'home' to Australian patients New government report reveals the emerging impact of generational reform Health department quietly launches major review of blood products supply Budget reveals

  • 220articles · 365d
  • 3+ hour agolatest article
  • Jan 21, 2026earliest in window
  • 90%with images
  • 159avg words
articles per day
Categories
  • Medical 203
  • Health 153
  • Health & Wellness 146
  • Business & Industrial 72
  • Economy, Business & Finance 33
  • Science & Technology 23
  • Finance & Business 13
  • Education 3

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

PharmaDispatch
pharmadispatch.com > news > melbourne-oncologist-takes-the-reins-at-australias-private-cancer-physicians-body

Melbourne oncologist takes the reins at Australia's private cancer physicians body

3+ day, 21+ hour ago   (154+ words) PharmaDispatch Melbourne oncologist takes the reins at Australia's private cancer physicians body After twelve years steering the Private Cancer Physicians of Australia through some of the most consequential fights in Australian cancer policy, Christopher Steer has handed the presidency to…...

PharmaDispatch
pharmadispatch.com > news > noxopharm-pushes-sofra-platform-towards-cancer-proof-of-concept

Noxopharm pushes Sofra platform towards cancer proof of concept

2+ week, 4+ day ago   (133+ words) PharmaDispatch Noxopharm pushes Sofra platform towards cancer proof of concept Noxopharm says new laboratory findings strengthen the case for using its Sofra technology to help the immune system recognise cancer cells after treatments such as chemotherapy or radiotherapy kill them....

PharmaDispatch
pharmadispatch.com > news > insurers-warn-cut-could-hit-australians-most-likely-to-need-cancer-care

Insurers warn cut could hit Australians most likely to need cancer care

2+ week, 5+ day ago   (124+ words) PharmaDispatch Insurers warn cut could hit Australians most likely to need cancer care The organisation has pointed to the potential impact on cancer treatment and care, highlighting that the policyholders impacted by the reduction are more likely than any other…...

PharmaDispatch
pharmadispatch.com > news > personalised-mrna-cancer-therapy-clears-phase-3-milestone-in-resected-melanoma

Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma - BioPharmaDispatch

3+ week, 3+ day ago   (135+ words) Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma PharmaDispatch Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma Professor Georgina Long, the study's principal investigator and medical director of Melanoma Institute Australia, said the findings could signal…...

PharmaDispatch
pharmadispatch.com > news > new-zealand-researchers-honoured-for-work-tackling-superbugs-and-blood-cancer

New Zealand researchers honoured for work tackling superbugs and blood cancer

3+ week, 3+ day ago   (138+ words) PharmaDispatch New Zealand researchers honoured for work tackling superbugs and blood cancer Two New Zealand scientists working at very different points of the medicines-development pipeline will be recognised tonight at Medicines New Zealand’s 2026 Value of Medicines Awards. … Opportunity #1 - biosimilar policy…...

PharmaDispatch
pharmadispatch.com > news > australian-company-announces-agreement-with-lilly-to-trial-lung-cancer-combination

Australian company announces agreement with Lilly to trial lung cancer combination

1+ mon, 1+ week ago   (119+ words) PharmaDispatch Australian company announces agreement with Lilly to trial lung cancer combination The Australian company had already worked with Lilly to prepare an advanced draft of the clinical study protocol before signing the significant agreement. … The HTA Review and the…...

PharmaDispatch
pharmadispatch.com > news > reform-for-patients-the-focus-of-private-cancer-physicians-summit

Reform for patients the focus of private cancer physicians summit

1+ mon, 2+ week ago   (107+ words) PharmaDispatch Reform for patients the focus of private cancer physicians summit The 2026 PCPA Cancer Summit will bring together leading cancer specialists, policymakers, patient advocates and industry partners in Melbourne on 28 and 29 August to explore solutions to improving access to treatment....

PharmaDispatch
pharmadispatch.com > news > bellberry-and-ascept-release-checklist-for-new-approach-methodologies-trials

Bellberry and ASCEPT release checklist for 'new approach methodologies' trials

1+ mon, 3+ week ago   (159+ words) PharmaDispatch Bellberry and ASCEPT release checklist for 'new approach methodologies' trials Professor Andrew Wilson AO, who chaired the Scientific Advisory Committee, said, "They may not entirely replace animal studies in every case, but they can often provide richer, more human…...

PharmaDispatch
pharmadispatch.com > news > our-access-our-medicines-our-vaccines-our-medical-technology

'Our access. Our medicines. Our vaccines. Our medical technology"

1+ mon, 3+ week ago   (113+ words) 'Our access. Our medicines. Our vaccines. Our medical technology' PharmaDispatch 'Our access. Our medicines. Our vaccines. Our medical technology' Medicines Australia and the Generic and Biosimilar Medicines Association are understood to be in active discussions with health department officials over…...

PharmaDispatch
pharmadispatch.com > news > an-opportunity-to-become-a-global-destination-for-paediatric-oncology-trials

An opportunity to become a global destination for paediatric oncology trials

1+ mon, 4+ week ago   (158+ words) PharmaDispatch An opportunity to become a global destination for paediatric oncology trials Thirteen representatives from government, industry, clinical care, research and patient advocacy met to identify practical actions to strengthen Australia’s paediatric oncology clinical trial ecosystem and attract greater investment…...